{
  "abstract": "Introduction Systemic sclerosis (SSc), or scleroderma, is a refractory autoimmune disorder marked by microvascular dysfunction and progressive fibrosis affecting the skin and multiple internal organs. Currently, treatment options for scleroderma-related fibrosis remain limited. The stromal vascular fraction (SVF), derived from adipose tissue, contains multiple regenerative cell components, including adipose-derived stem cells, has demonstrated promising therapeutic potential in various fibrotic diseases.Material and Methods SVF was obtained from the subcutaneous adipose tissue of C57BL/6 mice and delivered via different administration routes to evaluate its efficacy against skin and pulmonary fibrosis. Dermal thickness and collagen deposition were assessed through histological examination. SVF retention within fibrotic subcutaneous tissue was monitored longitudinally using in vivo imaging and immunofluorescence. Cutaneous vascular architecture and the production of antifibrotic factors—including hepatocyte growth factor (HGF) and basic fibroblast growth factor (FGF-2)—were analyzed via flow cytometry and immunofluorescence. Additionally, the functional roles and mechanistic contributions of key SVF subpopulations in attenuating fibrosis were investigated.Results SVF effectively alleviates skin and pulmonary fibrosis in mice through distinct mechanisms at different disease stages. In the early phase of skin fibrosis, SVF modulates vascular lesions and inflammation via endothelial cells, while in the late stage, stromal cells mediate antifibrotic effects by secreting reparative cytokines. The CD45- subpopulation is identified as the primary effector cell group responsible for these therapeutic effects. Additionally, tracheal delivery of SVF demonstrates superior efficacy compared to tail-vein injection in alleviating pulmonary fibrosis, with prolonged retention of SVF in the lungs under this administration route. These findings provide mechanistic insights into the therapeutic potential of SVF and support its clinical application in treating SSc-related fibrosis.Conclusions The CD45- negative subset of SVF exhibits strong therapeutic potential for mitigating skin fibrosis in systemic sclerosis. Intratracheal administration significantly potentiates the efficacy of SVF in treating pulmonary fibrosis. Collectively, these findings underscore the utility of SVF-based therapies for fibrotic diseases and provide a robust rationale for future clinical translation.Abstract P.013 Figure 1",
  "authors": [
    {
      "affiliations": [
        "State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Shanghai, China"
      ],
      "name": "Jiucun Wang"
    },
    {
      "affiliations": [
        "State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Shanghai, China"
      ],
      "name": "Zonghao Liu"
    },
    {
      "affiliations": [
        "State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Shanghai, China"
      ],
      "name": "Ziyu Wang"
    },
    {
      "affiliations": [
        "State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Shanghai, China"
      ],
      "name": "Mengqi Shi"
    },
    {
      "affiliations": [
        "State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Shanghai, China"
      ],
      "name": "Yahui Chen"
    },
    {
      "affiliations": [
        "Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China"
      ],
      "name": "Xiangguang Shi"
    }
  ],
  "title": "P.013 The stromal vascular fraction mitigates bleomycin-induced fibrosis in mice",
  "uid": "71ee7790-29b8-518a-b0ac-f6fa7d177cad"
}